GlassScriptPhysician profile
Sherif A Farag
NPI 1861467250
$97,211.21
in general payments reported to CMS, 2019-2025
52 companies · $3,667 in 2025
The $3,667 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $17K · 2021: $15K · 2022: $11K · 2023: $3,084 · 2024: $6,721 · 2025: $3,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,810 · Food and Beverage: $5,563 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,810.00 |
| Food and Beverage | $5,563.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59,235.74 | 2019-2025 | |
| Gilead Sciences, INC. | $23,248.36 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $7,036.96 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $895.40 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $826.83 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $428.23 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $371.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $366.15 | 2019-2024 | Linzess |
| Lilly USA, LLC | $330.45 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Redhill Biopharma INC. | $309.00 | 2020-2024 | Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $305.82 | 2019-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $299.29 | 2022-2025 | Dupixent |
| Amgen INC. | $259.59 | 2019-2024 | Repatha, Otezla |
| Intercept Pharmaceuticals, INC. | $253.11 | 2019-2023 | Ocaliva |
| Astrazeneca Pharmaceuticals LP | $243.83 | 2019-2021 |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Farag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.